Tested three times. Metformin indicated by mass spectra degradation peaks. A standard was analyzed by GCMS with BSTFA derivitization, two peaks were produced. The sample was analyzed the same way, but only one of two peaks were detected in the sample: NOT both as would be expected.
This could be explained by some component in the tablet interfering with our procedure using BSTFA derivitization consumption. We think metformin might be present, but cannot positively confirm it in this case.
(Dec 27 2017) Re-analysis with certified metformin standard complete. Sample appears to be similar to metformin but its GC and MS spectra do not precisely match the certified standard using our methodology. It's possible that they don't match because we are matching a pure lab standard against the contents of a tablet.
(Dec 12 2017) Re-analysis of this tablet is in progress and should be completed this week. Please check back.
(Dec 4 2017) Check back after Dec 12 for an update to this sample, it will be re-analyzed by the lab to confirm the initial identification of Metformin, after they receive a certified standard for Metformin.
Round white tablet with '850' (and no break line).
Send in a sample for testing
DrugsData tests all psychoactive drugs including ecstasy tablets, powders, research chemicals, novel pschoactive substances, and other drugs through our licensed laboratory. Ecstasy/Molly tablets cost $100. Recreational drug powder/crystal/blotter costs $100. Pharmaceuticals, supplements and all others cost $150 per analysis.
Should the public have access to independent analysis of the products they consume?
The vast majority of analyses of over-the-counter, prescription, and recreational drugs are performed in secret with no independent oversite or review. No other historical record, free from politically-controlled agencies, is currently available in North America nor most other parts of the world.
DrugsData, a project of Erowid Center, needs the support of professionals, students, parents, individuals with means, and small foundations for a total yearly budget of around $120,000 USD. Erowid Center's general budget and the co-pays we require fund most of this cost.
(Dec 12 2017) Re-analysis of this tablet is in progress and should be completed this week. Please check back.
(Dec 4 2017) Check back after Dec 12 for an update to this sample, it will be re-analyzed by the lab to confirm the initial identification of Metformin, after they receive a certified standard for Metformin.